Welcome to our dedicated page for Revolution Medicines SEC filings (Ticker: RVMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Revolution Medicines, Inc. (RVMD) provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed late-stage clinical oncology company, Revolution Medicines uses these filings to report on its financial condition, clinical and regulatory milestones, and significant corporate agreements related to its RAS(ON) inhibitor pipeline.
Investors reviewing RVMD’s filings will find current reports on Form 8-K that describe material events such as clinical data updates, FDA designations and strategic financings. For example, the company has filed 8-Ks detailing Breakthrough Therapy Designation and a Commissioner’s National Priority Voucher for daraxonrasib, pipeline updates in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and a Royalty Purchase Agreement with Royalty Pharma covering potential future net product sales of daraxonrasib and zoldonrasib.
Other 8-K filings discuss term loan facilities linked to regulatory approvals and sales milestones, leadership changes at the board and executive levels, and the listing of Revolution Medicines’ common stock (RVMD) and warrants (RVMDW) on The Nasdaq Stock Market LLC. Periodic filings such as Forms 10-Q and 10-K, referenced in the company’s forward-looking statements, provide more comprehensive discussions of risk factors, research and development activities, and overall business strategy.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that highlight key points, such as how financing agreements relate to daraxonrasib and zoldonrasib, or what new clinical or regulatory information is disclosed. Users can quickly identify items related to quarterly results (10-Q), annual reports (10-K), and current reports (8-K), as well as monitor registered securities like RVMD and RVMDW.
This page helps readers understand how Revolution Medicines reports on its RAS(ON) inhibitor programs, financial position and significant corporate events through its SEC disclosures, with AI tools simplifying navigation of complex oncology and financing information.
Revolution Medicines, Inc. director and officer Mark A. Goldsmith exercised stock options and sold shares of common stock. He exercised options for 23,244 shares at an exercise price of $4.09 and 96,756 shares at $4.73, receiving an equal number of common shares. He then sold 120,000 common shares at a weighted average price of $150.0874 in open-market transactions made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024. After these transactions, he held 276,698 common shares directly, including 201,150 restricted stock units, and additional indirect holdings through family trusts.
Revolution Medicines, Inc. entered into a material financing by issuing $500,000,000 of 0.50% Convertible Senior Notes due 2033. These senior unsecured notes pay 0.50% interest semi-annually and mature on May 1, 2033 unless earlier repurchased, redeemed or converted.
Holders can generally convert only upon certain events until February 1, 2033, and at any time thereafter until shortly before maturity. The initial conversion rate is 5.0302 shares per $1,000 principal, implying an initial conversion price of about $198.80 per share. The company may settle conversions in cash, stock, or a combination.
Beginning May 6, 2030, the company may redeem the notes in cash if its stock trades above 130% of the conversion price for specified trading-day periods, subject to a minimum amount of notes remaining outstanding. Upon certain “Fundamental Change” events, holders can require cash repurchase at par plus accrued interest.
Revolution Medicines, Inc. completed a major equity financing, selling 10,563,381 common shares at $142.00 per share, with underwriters exercising an option for an additional 1,584,506 shares. The company expects net proceeds of about $1,650.4 million from this equity offering.
Concurrently, the company entered into an agreement to sell $500,000,000 aggregate principal amount of 0.50% Convertible Senior Notes due 2033, with closing expected on April 17, 2026, subject to customary conditions. Both transactions were conducted under an automatic shelf registration and involved standard underwriting terms and indemnification provisions.
Revolution Medicines, Inc. is offering 10,563,381 shares of its common stock pursuant to a prospectus supplement. The public offering price is $142.00 per share, with estimated net proceeds to the issuer of approximately $1,435.0 million after underwriting discounts and estimated offering expenses. The prospectus supplement states an underwriter option to purchase up to 1,584,506 additional shares for 30 days and notes a concurrent, separate offering of $500,000,000 principal amount of 0.50% convertible senior notes due 2033; neither offering is contingent on the other. The company reported 197,001,401 shares outstanding as of December 31, 2025, and the prospectus discloses 28.6 million shares subject to outstanding options, warrants or RSUs as of that date.
Revolution Medicines, Inc. is offering $500,000,000 aggregate principal amount of 0.50% convertible senior notes due May 1, 2033. Interest accrues at 0.50% paid semi‑annually beginning November 1, 2026. The initial conversion rate is 5.0302 shares per $1,000 principal (= ~$198.80 per share). The company may settle conversions in cash, stock or a combination, and may redeem notes under specified stock‑price conditions on or after May 6, 2030. Concurrently, the company has a separate common stock offering of 10,563,381 shares, plus an underwriter option for up to 1,584,506 additional shares. Net proceeds to the company from the notes offering are estimated at approximately $486.8 million, to be used for general corporate purposes.
Morgan Stanley Smith Barney LLC filed a Form 144 notifying the sale of 120,000 shares of Common Stock by an affiliated seller, dated 04/15/2026. The filing lists an aggregate sale value of $17,641,200.00 and identifies NASDAQ as the market. The record also lists prior 10b5-1 sales in March 2026 including 30,000 and smaller lots.
Revolution Medicines is offering $750,000,000 of common stock, equal to 7,777,662 shares at an assumed public offering price of $96.43 per share. The prospectus supplement also describes a concurrent offering of $250,000,000 aggregate principal amount of convertible senior notes due 2033 (plus a $37,500,000 option).
The company reported 197,001,401 shares outstanding as of December 31, 2025. The shelf registration permits primary sales of common stock; the underwriters have a 30-day option to purchase up to $112,500,000 of additional shares. Completion of the equity offering is not contingent on the concurrent convertible note offering, and vice versa.
Revolution Medicines is offering $750,000,000 of common stock, equal to 7,777,662 shares at an assumed public offering price of $96.43 per share. The prospectus supplement also describes a concurrent offering of $250,000,000 aggregate principal amount of convertible senior notes due 2033 (plus a $37,500,000 option).
The company reported 197,001,401 shares outstanding as of December 31, 2025. The shelf registration permits primary sales of common stock; the underwriters have a 30-day option to purchase up to $112,500,000 of additional shares. Completion of the equity offering is not contingent on the concurrent convertible note offering, and vice versa.
Revolution Medicines, Inc. is offering $250,000,000 aggregate principal amount of % convertible senior notes due 2033, with an underwriter option of up to $37,500,000. The notes pay semi‑annual interest, mature May 1, 2033 and are convertible into common stock based on an initial conversion rate and conversion price.
The offering is concurrent with a separate common stock offering of $750,000,000 (plus up to $112,500,000 option). No listing is planned for the notes; common stock trades on Nasdaq under RVMD and last reported sale price was $96.43 per share.
Revolution Medicines, Inc. is offering $250,000,000 aggregate principal amount of % convertible senior notes due 2033, with an underwriter option of up to $37,500,000. The notes pay semi‑annual interest, mature May 1, 2033 and are convertible into common stock based on an initial conversion rate and conversion price.
The offering is concurrent with a separate common stock offering of $750,000,000 (plus up to $112,500,000 option). No listing is planned for the notes; common stock trades on Nasdaq under RVMD and last reported sale price was $96.43 per share.
Revolution Medicines reported strong topline results from its global Phase 3 RASolute 302 trial of oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. Daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with standard intravenous chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). The therapy also showed statistically significant, clinically meaningful gains in progression-free survival and was generally well tolerated, with a manageable safety profile and no new safety signals. Based on this first interim analysis, all progression-free and overall survival endpoints are considered final, and the company plans to submit these data to global regulators, including a future U.S. New Drug Application under a Commissioner’s National Priority Voucher.
Revolution Medicines reported strong topline results from its global Phase 3 RASolute 302 trial of oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. Daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with standard intravenous chemotherapy, with a hazard ratio of 0.40 (p < 0.0001). The therapy also showed statistically significant, clinically meaningful gains in progression-free survival and was generally well tolerated, with a manageable safety profile and no new safety signals. Based on this first interim analysis, all progression-free and overall survival endpoints are considered final, and the company plans to submit these data to global regulators, including a future U.S. New Drug Application under a Commissioner’s National Priority Voucher.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting 0 shares (0%) of Revolution Medicines Inc common stock (CUSIP 76155X100). The filing states an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that disaggregated certain subsidiaries' holdings from The Vanguard Group, Inc. The Schedule lists the filing address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
The filing declares no sole or shared voting or dispositive power over any Revolution Medicines shares and confirms ownership of 5% or less of the class.